M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

Phase 1

Completed

Conditions: COL6A3 Positive
HLA-A*0201 Positive Cells Present
Recurrent Ovarian Carcinoma
PRAME Positive

Interventions: Biological: Aldesleukin
Drug: CD8-Positive T-Lymphocyte
Drug: Cyclophosphamide
Procedure: Leukapheresis
Biological: Utomilumab

First Posted Date: 2017-10-24

Last Posted Date: 2024-11-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT03318900

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy

Phase 2

Completed

Conditions: Stage II Bladder Cancer AJCC v8
Stage IIIB Bladder Cancer AJCC v8
Stage I Bladder Cancer AJCC v8
Stage III Bladder Cancer AJCC v8
Stage IIIA Bladder Cancer AJCC v8

Interventions: Biological: Pembrolizumab

First Posted Date: 2017-10-24

Last Posted Date: 2024-06-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT03319745

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery

Phase 2

Active, not recruiting

Conditions: Recurrent Dedifferentiated Liposarcoma
Recurrent Undifferentiated Pleomorphic Sarcoma
Dedifferentiated Liposarcoma
Resectable Dedifferentiated Liposarcoma
Undifferentiated Pleomorphic Sarcoma
Resectable Undifferentiated Pleomorphic Sarcoma

Interventions: Biological: Ipilimumab
Biological: Nivolumab
Radiation: Radiation Therapy

First Posted Date: 2017-10-12

Last Posted Date: 2025-04-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 32

Registration Number: NCT03307616

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Pembrolizumab in Treating Participants with Unresectable Thymoma or Thymic Cancer

Phase 1

Recruiting

Conditions: Stage III Thymoma AJCC V8
Stage IIIA Thymoma AJCC V8
Stage IIIB Thymoma AJCC V8
Stage IV Thymoma AJCC V8
Stage IVA Thymoma AJCC V8
Stage IVB Thymoma AJCC V8
Unresectable Thymic Carcinoma

Interventions: Biological: Pembrolizumab

First Posted Date: 2017-09-27

Last Posted Date: 2025-01-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 37

Registration Number: NCT03295227

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Colorectal Carcinoma
Stage IV Colorectal Cancer AJCC v8
Stage IVA Colorectal Cancer AJCC v8
Stage IVB Colorectal Cancer AJCC v8
Stage IVC Colorectal Cancer AJCC v8

Interventions: Biological: Cetuximab
Drug: Irinotecan Hydrochloride
Other: Pharmacodynamic Study
Biological: Utomilumab

First Posted Date: 2017-09-25

Last Posted Date: 2025-05-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT03290937

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

IACS-010759 in Advanced Cancers

Phase 1

Completed

Conditions: Prognostic Stage IIIA Breast Cancer AJCC v8
Stage IV Pancreatic Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Metastatic Malignant Solid Neoplasm
Prognostic Stage III Breast Cancer AJCC v8
Stage IIB Pancreatic Cancer AJCC v8
Stage III Pancreatic Cancer AJCC v8
Triple-Negative Breast Carcinoma
Anatomic Stage IIIB Breast Cancer AJCC v8
Prognostic Stage IV Breast Cancer AJCC v8

Interventions: Drug: Oxidative Phosphorylation Inhibitor IACS-010759
Other: Pharmacodynamic Study
Other: Pharmacokinetic Study

First Posted Date: 2017-09-25

Last Posted Date: 2020-11-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT03291938

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

RCT of QPS vs General Information Sheet

Not Applicable

Active, not recruiting

Conditions: Caregiver
Advanced Malignant Neoplasm
Physician

Interventions: Other: Informational Intervention
Other: Questionnaire Administration

First Posted Date: 2017-09-19

Last Posted Date: 2025-04-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 207

Registration Number: NCT03287492

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

Phase 1

Active, not recruiting

Conditions: Newly Diagnosed Primary Amyloidosis
Refractory Primary Amyloidosis
Recurrent Primary Amyloidosis

Interventions: Biological: Daratumumab
Drug: Dexamethasone
Drug: Ixazomib

First Posted Date: 2017-09-14

Last Posted Date: 2025-05-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT03283917

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma

Phase 1

Withdrawn

Conditions: Multiple Myeloma
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic

Interventions: Drug: Nivolumab
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Ipilimumab

First Posted Date: 2017-09-14

Last Posted Date: 2017-09-20

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT03283046

Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Ibrutinib

First Posted Date: 2017-09-13

Last Posted Date: 2025-04-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT03282396

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy